The present invention relates to a deproteinised calf blood preparation for use in prevention or treatment of diabetic peripheral polyneuropathy, wherein the deproteinised calf blood preparation is administered parenterally at least once and wherein the parenteral administration is followed by a period of enteral administration. Preferably, 20 doses of deproteinised calf blood preparation is administered intravenously once daily for a period of 20-36 days followed by an oral administration of the deproteinised calf blood preparation for 140 days. In a preferred embodiment of the present invention, the deproteinised calf blood preparation is the medicament Actovegin®.
